Craft
Agenus

Agenus

Revenue

$295.7 M

FY, 2021

Market Capitalization

$593.3 M

2022-09-19

Agenus Summary

Company summary

Overview
Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.
Type
Public
Founded
1994
HQ
Lexington, MA, US | view all locations
Website
http://agenusbio.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Garo H. Armen

    Garo H. Armen, Chairman, Chief Executive Officer

  • Steven O'Day

    Steven O'Day, Chief Medical Officer

  • Alfred Dadson

    Alfred Dadson, Chief Manufacturing Officer

  • Julie Desander

    Julie Desander, Chief Business Officer

LocationsView all

4 locations detected

  • Lexington, MA HQ

    United States

    3 Forbes Rd

  • Berkeley, CA

    United States

    793 Heinz Ave

  • New York, NY

    United States

    149 5th Ave #500

  • Cambridge, England

    United Kingdom

    315 Science Park Milton Road

Agenus Financials

Summary financials

Revenue (Q2, 2022)
$20.9M
Gross profit (Q2, 2022)
$18.9M
Net income (Q2, 2022)
($49.2M)
Cash (Q2, 2022)
$228.4M
EBIT (Q2, 2022)
($44.6M)
Enterprise value
$392.4M

Footer menu